Chordia Therapeutics Inc. (TYO:190A)

Japan flag Japan · Delayed Price · Currency is JPY
99.00
-2.00 (-1.98%)
Jun 4, 2026, 3:30 PM JST
Market Cap7.30B -53.8%
Revenue (ttm)n/a
Net Income-1.44B
EPS-20.64
Shares Out 73.73M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume445,300
Open100.00
Previous Close101.00
Day's Range99.00 - 102.00
52-Week Range98.00 - 241.00
Betan/a
Analystsn/a
Price Targetn/a
Earnings DateJul 15, 2026

About Chordia Therapeutics

Chordia Therapeutics Inc., a biotech company, engages in research and development of anti-cancer drugs that targets RNA deregulation stress in Japan. It develops CLK CTX-712, a CLK inhibitor, which is Phase 1 clinical trial for the treatment of relapsed or refractory malignant cancers.; CTX-177, a small-molecule inhibitor of MALT1; CDK12 inhibitor CTX-439; and GCN2 inhibitor CRD-1968099. Chordia Therapeutics Inc. was incorporated in 2017 and is based in Fujisawa, Japan. [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
Founded 2017
Employees 23
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 190A
Full Company Profile

Financial Performance

Financial Statements